A detailed history of Profund Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Profund Advisors LLC holds 27,920 shares of VRTX stock, worth $12.6 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
27,920
Previous 29,546 5.5%
Holding current value
$12.6 Million
Previous $13.8 Million 6.23%
% of portfolio
0.5%
Previous 0.52%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$460.0 - $505.78 $747,960 - $822,398
-1,626 Reduced 5.5%
27,920 $13 Million
Q2 2024

Aug 13, 2024

BUY
$392.81 - $485.53 $1.25 Million - $1.55 Million
3,194 Added 12.12%
29,546 $13.8 Million
Q1 2024

May 08, 2024

SELL
$407.69 - $446.08 $705,303 - $771,718
-1,730 Reduced 6.16%
26,352 $11 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $1.2 Million - $1.44 Million
3,495 Added 14.21%
28,082 $11.4 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $1.57 Million - $1.69 Million
4,653 Added 23.34%
24,587 $8.55 Million
Q2 2023

Aug 10, 2023

BUY
$314.42 - $351.91 $304,044 - $340,296
967 Added 5.1%
19,934 $7.01 Million
Q1 2023

May 11, 2023

SELL
$283.23 - $323.1 $6.32 Million - $7.2 Million
-22,299 Reduced 54.04%
18,967 $5.98 Million
Q4 2022

Feb 02, 2023

SELL
$285.76 - $321.48 $5,143 - $5,786
-18 Reduced 0.04%
41,266 $11.9 Million
Q3 2022

Nov 04, 2022

SELL
$273.83 - $305.53 $552,588 - $616,559
-2,018 Reduced 4.66%
41,284 $12 Million
Q2 2022

Aug 01, 2022

SELL
$234.96 - $292.55 $1.36 Million - $1.7 Million
-5,796 Reduced 11.8%
43,302 $12.2 Million
Q1 2022

May 10, 2022

SELL
$221.42 - $260.97 $2.11 Million - $2.48 Million
-9,510 Reduced 16.23%
49,098 $12.8 Million
Q4 2021

Feb 08, 2022

SELL
$177.01 - $223.45 $1.52 Million - $1.92 Million
-8,612 Reduced 12.81%
58,608 $12.9 Million
Q3 2021

Nov 12, 2021

BUY
$181.39 - $202.99 $6,711 - $7,510
37 Added 0.06%
67,220 $12.2 Million
Q2 2021

Aug 12, 2021

SELL
$187.49 - $221.1 $413,602 - $487,746
-2,206 Reduced 3.18%
67,183 $13.5 Million
Q1 2021

May 14, 2021

SELL
$207.02 - $241.31 $411,969 - $480,206
-1,990 Reduced 2.79%
69,389 $14.9 Million
Q4 2020

Feb 09, 2021

BUY
$207.01 - $276.09 $1.08 Million - $1.44 Million
5,230 Added 7.91%
71,379 $16.9 Million
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $2.17 Million - $2.58 Million
-8,501 Reduced 11.39%
66,149 $18 Million
Q2 2020

Aug 03, 2020

BUY
$225.48 - $295.8 $2.21 Million - $2.89 Million
9,783 Added 15.08%
74,650 $21.7 Million
Q1 2020

May 15, 2020

SELL
$199.77 - $247.81 $4.21 Million - $5.23 Million
-21,092 Reduced 24.54%
64,867 $15.4 Million
Q4 2019

Feb 18, 2020

BUY
$166.71 - $223.91 $1.45 Million - $1.95 Million
8,698 Added 11.26%
85,959 $18.8 Million
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $674,727 - $759,398
-4,059 Reduced 4.99%
77,261 $13.1 Million
Q2 2019

Aug 13, 2019

SELL
$164.61 - $190.37 $1.05 Million - $1.22 Million
-6,390 Reduced 7.29%
81,320 $14.9 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $219,725 - $261,287
1,342 Added 1.55%
87,710 $16.1 Million
Q4 2018

Feb 14, 2019

SELL
$151.91 - $192.21 $3.17 Million - $4.01 Million
-20,840 Reduced 19.44%
86,368 $14.3 Million
Q3 2018

Nov 13, 2018

BUY
$167.73 - $192.74 $1.58 Million - $1.82 Million
9,424 Added 9.64%
107,208 $20.7 Million
Q2 2018

Aug 13, 2018

SELL
$145.72 - $169.96 $677,306 - $789,974
-4,648 Reduced 4.54%
97,784 $16.6 Million
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $1.13 Million - $1.33 Million
-7,484 Reduced 6.81%
102,432 $16.7 Million
Q4 2017

Feb 14, 2018

SELL
$137.28 - $155.55 $1.52 Million - $1.73 Million
-11,097 Reduced 9.17%
109,916 $16.5 Million
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $1.43 Million - $1.57 Million
9,680 Added 8.69%
121,013 $18.4 Million
Q2 2017

Aug 11, 2017

BUY
N/A
111,333
111,333 $14.3 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Profund Advisors LLC Portfolio

Follow Profund Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.